Dear Colleagues,
Welcome to the January 2011 issue of Science Speaks!
In this month's issue of Science Speaks we are featuring emerging countries in Central and Eastern Europe. We have included two articles written by our life science expert on outsourcing clinical trials to CEE countries and Russia.
Take a look also at this month's Biotech News section which discusses the competition between generic and patented innovative drugs in CEE.
Please visit our website at www.languageconnections.com to learn more about our services and publications.
Enjoy!
|
Today's Russian Clinical Trial Environment
|
Despite the recent global economic downturn, in Russia growth of the clinical
research sectors continues. In addition to a number of other factors, Russia's excellent patient recruitment rates and solid reputation for conducting quality clinical
research have played a significant role. Today, Russia is one of
the five most prominent emerging countries conducting clinical research, with an increasing number of foreign-sponsored trials in particular. Trials |
Clinical Trials in CEE: The Challenge of Dealing
|
 Central and Eastern Europe
(CEE) is a prominent newly emerging regions
for outsourcing clinical research. Among the nineteen countries that make up the region, several are European Union members. As a result, many CEE countries have adopted EU legislature and regulatory procedures.
These countries offer several advantages, including highly successful patient enrollment, many specialized medical centers, and significantly reduced costs. Countries such as Poland, Czech Republic, and Hungary, as well as several countries of the former Soviet Union, are particularly exhibiting exponential growth.
Read more...
|
Biotech News: Cultural Preference for Generic Drugs in CEE & Russia?
|
 Across Russia and countries in Central and
Eastern Europe (CEE) there is fierce competition between patented
drugs, and branded and commodity generics. While consumers prefer the status of
innovative patented drugs produced by established Western pharma
giants, they are culturally attached to inexpensive,
government-subsidized products. |
